Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Senators press Novo Nordisk CEO on why Ozempic and Wegovy cost less abroad
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for brand-name prescriptions.
Novo Nordisk CEO spars with lawmakers over Ozempic, Wegovy prices
The CEO of Novo Nordisk faced pointed questions about the cost of Ozempic and Wegovy on Capitol Hill Tuesday, as lawmakers pressed the Danish pharmaceutical giant to cut the prices of its blockbuster diabetes and obesity medications.
'Stop ripping us off,' says Sen. Sanders, but Novo CEO blames PBMs for high Wegovy prices
Novo Nordisk has a price fix solution for uninsured patients with diabetes, but not for HSA holders or people with normal blood sugar.
Novo Nordisk CEO grilled by Congress over Ozempic, Wegovy prices in US
For the millions of people living with diabetes or obesity, drugs like Ozempic and Wegovy can significantly improve their health.
Sanders leads HELP Committee hearing with Novo Nordisk CEO on Ozempic and Wegovy prices
Chairman of the Senate Committee on Health, Education, Labor, and Pensions (HELP), today led the committee in a hearing to examine why Novo Nordisk charges the American people the highest prices in the world for its lifesaving drugs,
‘You’re hiding behind your opaqueness’: Senators question Novo Nordisk CEO over high cost of Ozempic, Wegovy
Bipartisan lawmakers grilled Novo Nordisk CEO Lars Fruergaard Jørgensen in a Senate hearing in an attempt to pick apart the high cost of GLP-1 drugs.
Novo Nordisk's CEO took the Washington hot seat over Ozempic prices. 3 takeaways from his testimony
CEO Lars Fruergaard Jørgensen agreed today, during a Senate committee hearing, to sit down with lawmakers and pharmacy benefit managers (PBMs) to look into the possibility of cutting list prices for the company’s popular diabetes and weight-loss drugs.
Novo Nordisk CEO Stands by Drug Pricing of Ozempic, Wegovy
Novo Nordisk Chief Executive Lars Jorgensen challenged Medicare's new role negotiating prescription drug prices during his testimony before a Senate committee on the company's blockbuster diabetes and weight-loss drugs.
Novo Nordisk CEO Grilled by Congress Over Price of Ozempic
During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions over the company's high prices for its blockbuster drugs Ozempic and Wegovy.
Ozempic maker's CEO grilled over price of weight loss drugs
The CEO of the company that makes Ozempic faced a Bernie Sanders-led Senate hearing on Tuesday.
2d
Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers.
Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.
13h
RFK Jr. bashes Ozempic buzz and Novo Nordisk profits
Robert F. Kennedy Jr. criticized Ozempic and Danish pharmaceutical company Novo Nordisk, arguing that fixing the food supply ...
In Depth
1d
In Depth
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on ...
c-span
3d
Novo Nordisk CEO Testifies on Ozempic & Wegovy Prices
as
Novo
Nordisk
CEO Lars Jergensen testified on the company’s pricing for its diabetes and weight loss drugs, Ozempic and
Wegovy
, respectively. Mr. Jergensen answered questions on a variety of ...
23h
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
The healthcare company's pivot into a new set of technologies will have many implications for the stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Ozempic
United States
Lars Fruergaard Jorgensen
European Medicines Agency
Feedback